Dimethyl fumarate for multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 4, 2014, Pages

  Xu, Zhu ^a   Zhang, Feng ^b   Sun, Fang Li ^b   Gu, Ke Feng ^b   Dong, Shuai ^b   He, Dian ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b No 6 People's Hospital of Jinan   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE;

DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 84955440233     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011076     Document Type: Review

References (45)

1. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al.Effects of dimethyl fumarate on neuroprotection and immunomodulation. Journal of Neuroinflammation 2012;9:163.
2. Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, et al.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology 2013;260(9):2297-305.
3. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al.Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47(1):129-39.
4. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129(3):606-16.
5. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, et al.Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD008933].
6. Fischer JS, La Rocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis 1999;5(4):251-9.
7. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al.Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. The New England Journal of Medicine 2012;367(12):1087-97.
8. Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, et al.Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. Journal of Experimental Medicine 2011;208(11):2291-303.
9. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. Journal of Neurology 2004;251(3):261-8.
10. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. The New England Journal of Medicine 2012;367(12):1098-107.
11. Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows. Brozek J, Oxman A, Schünemann H, 2008.
12. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
13. Hutchinson M, Fox RJ, Miller DH, Phillips JT, Kita M, Havrdova E, et al.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Journal of Neurology 2013;260(9):2286-96.
14. Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, et al.Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research Opinion 2014; Vol. 30, issue 4:613-27.
15. Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicological Sciences 2010;114(2):237-46.
16. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al.Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372(9648):1463-72.
17. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al.Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Multiple Sclerosis 2012;18(3):314-21.
18. Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al.Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study. Multiple Sclerosis 2014; Vol. 20, issue 2:243-52.
19. Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Multiple Sclerosis 2012;18(2 Suppl):7-15.
20. Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(1):11-25.
21. Karampampa K, Gustavsson A, van Munster ET, Hupperts RM, Sanders EA, Mostert J, et al.Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands. Journal of Medical Economics 2013;16(7):939-50.
22. Kita M, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Sarda SP, et al.Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Multiple Sclerosis 2014; Vol. 20, issue 2:253-7.
23. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
24. Lee DH, Linker RA, Gold R. Spotlight on fumarates. International MS Journal 2008;15(1):12-8.
25. Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. International Journal of Molecular Sciences 2012;13(9):11783-803.
26. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al.Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134(3):678-92.
27. Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, et al.Pharmacokinetics of oral fumarates in healthy subjects. British Journal of Clinical Pharmacology 2004;58(4):429-32.
28. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
29. Lukashev M, Zeng W, Goelz S, Lee D, Linker R, Gold R, et al.Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. Multiple Sclerosis 2007;13(Suppl 2):149.
30. MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, et al.BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. Journal of Neurology 2011;258(3):449-56.
31. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al.Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001;50(1):121-7.
32. Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse: the patient's perspective. Patient 2012;5(1):57-69.
33. Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, et al.Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. Journal of Biological Chemistry 2012;287(33):28017-26.
34. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al.Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology 2005;58(6):840-6.
35. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 2011;69(2):292-302.
36. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(8):227-31.
37. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
38. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, et al.Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. Journal of Pharmacology and Experimental Therapeutics 2012;341(1):274-84.
39. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clinical and Experimental Immunology 2006;145(1):101-7.
40. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, et al.Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. European Journal of Neurology 2006;13(6):604-10.
41. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al.Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247-56.
42. Tullman MJ, Oshinsky RJ, Lublin FD, Cutter GR. Clinical characteristics of progressive relapsing multiple sclerosis. Multiple Sclerosis 2004;10(4):451-4.
43. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of Life Research 1995;4(3):187-206.
44. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
45. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethyl fumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. Journal of Neuroinflammation 2010;7:30.